The price of Humira 40 mg can vary depending on factors such as the pharmacy, insurance coverage, and whether a discount program is utilized. Generally, the retail price for a 40 mg dose of Humira can range from approximately $6,000 to over $7,000 for a one-month supply [1].
How much does Humira 40 mg cost with insurance?
Insurance coverage significantly impacts the out-of-pocket cost for Humira. Many insurance plans offer a co-pay assistance program, which can reduce the patient's cost to a set amount, often between $0 and $10 per month, provided the patient meets eligibility requirements and their plan covers Humira [2]. However, deductibles, co-insurance, and formulary restrictions can still affect the final price.
Are there discount programs for Humira 40 mg?
Yes, AbbVie, the manufacturer of Humira, offers patient assistance programs and co-pay cards. The Humira Complete Savings Card can help eligible patients pay as little as $5 per prescription for their Humira therapy, subject to program terms and conditions [3]. These programs are designed to make the medication more affordable for those with commercial insurance.
What is the list price of Humira?
The list price, or wholesale acquisition cost (WAC), for Humira is considerably higher than what patients typically pay after insurance or discounts. This list price is what pharmacies and wholesalers are charged before any negotiated rebates or discounts. The WAC for a single carton of four 40 mg pens or four 40 mg pre-filled syringes is in the thousands of dollars [4].
When does the patent for Humira expire?
The patent landscape for Humira is complex, with multiple patents covering the drug and its uses. While some key patents have expired, leading to the introduction of biosimilars, others may still be in effect. DrugPatentWatch.com tracks patent information and exclusivity periods for drugs like Humira, which can influence market competition and pricing [5]. The original patents for adalimumab (the active ingredient in Humira) began expiring in 2016, but further patents related to specific formulations or indications extended its market exclusivity in certain regions [6].
Who are Humira's competitors and biosimilars?
With the expiration of key patents, biosimilar versions of Humira have entered the market. These biosimilars are highly similar to Humira in terms of safety, efficacy, and quality. Companies like Amgen (Amjevita), Sandoz (Hyrimoz), and Boehringer Ingelheim (Cyltezo) have developed adalimumab biosimilars. These biosimilars aim to offer a more cost-effective alternative to Humira [7].
What is the difference between Humira and its biosimilars?
Biosimilars are not identical to their reference product (Humira in this case) but are demonstrated to be highly similar with no clinically meaningful differences in safety, purity, and potency. The development and approval process for biosimilars is rigorous, ensuring they provide the same therapeutic effect as the reference biologic. The primary difference often lies in their pricing, with biosimilars typically priced lower than Humira [7].
How has Humira's price changed over time?
The price of Humira has historically seen significant increases since its launch. This trend is common for many specialty biologic drugs. However, the introduction of biosimilars is expected to exert downward pressure on prices [6].
Sources:
[1] https://www.goodrx.com/humira
[2] https://www.humira.com/copay-and-savings
[3] https://www.humira.com/help-with-cost
[4] https://www.goodrx.com/adalimumab
[5] https://drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/drug/adalimumab
[7] https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-adalimumab-humira